Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) has earned a consensus recommendation of “Buy” from the six research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $49.60.
A number of brokerages have recently issued reports on MIRM. SVB Leerink boosted their price objective on Mirum Pharmaceuticals from $42.00 to $46.00 and gave the stock an “outperform” rating in a report on Friday, January 28th. Raymond James boosted their price objective on Mirum Pharmaceuticals from $70.00 to $74.00 and gave the stock a “strong-buy” rating in a report on Friday, March 11th.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Citigroup Inc. raised its position in shares of Mirum Pharmaceuticals by 348.7% in the fourth quarter. Citigroup Inc. now owns 1,844 shares of the company’s stock valued at $29,000 after buying an additional 1,433 shares in the last quarter. Los Angeles Capital Management LLC raised its position in Mirum Pharmaceuticals by 7.0% during the third quarter. Los Angeles Capital Management LLC now owns 22,410 shares of the company’s stock valued at $446,000 after purchasing an additional 1,470 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its position in Mirum Pharmaceuticals by 6.6% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 25,322 shares of the company’s stock valued at $404,000 after purchasing an additional 1,574 shares in the last quarter. Geode Capital Management LLC raised its position in Mirum Pharmaceuticals by 1.4% during the third quarter. Geode Capital Management LLC now owns 176,673 shares of the company’s stock valued at $3,519,000 after purchasing an additional 2,402 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Mirum Pharmaceuticals by 12.9% during the fourth quarter. JPMorgan Chase & Co. now owns 22,569 shares of the company’s stock valued at $360,000 after purchasing an additional 2,573 shares in the last quarter. Institutional investors own 78.82% of the company’s stock.
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Rating) last posted its quarterly earnings results on Wednesday, March 9th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.31). The company had revenue of $3.14 million during the quarter, compared to analyst estimates of $76.60 million. On average, sell-side analysts anticipate that Mirum Pharmaceuticals will post -5.01 earnings per share for the current year.
About Mirum Pharmaceuticals (Get Rating)
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.
- Get a free copy of the StockNews.com research report on Mirum Pharmaceuticals (MIRM)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.